Intra-Cellular Therapies, Inc.
ITCIDrugs in Pipeline
13
Phase 3 Programs
8
Upcoming Catalysts
5
Next Catalyst
May 15, 2026
TomorrowMarket Overview
Stock performance and key metrics
5 upcoming, 0 past
Lumateperone Phase 3 Results Expected
Primary completion for Lumateperone trial (NCT06462612) in Bipolar Disorder, Manic
Source4 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Risperidone
Schizophrenia
ITI-007
Schizophrenia
Lumateperone
Major Depressive Disorder
Lumateperone low dose
Irritability Associated With Autism Spectrum Disorder
Lumateperone 42 mg
Schizophrenia
Lumateperone (ITI-007)
Bipolar Depression
Lumateperone high dose
Irritability Associated With Autism Spectrum Disorder
ITI-007 (Lumateperone)
Bipolar Depression
ITI-1284 20 mg
Generalized Anxiety Disorder
ITI-1284
Agitation Associated With Alzheimer's Dementia
Lenrispodun
Parkinson Disease
ITI-1284 10 mg
Generalized Anxiety Disorder
ITI-214
Heart Failure, Systolic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Risperidone | Phase 3 | Schizophrenia | - | - |
ITI-007 | Phase 3 | Schizophrenia | - | - |
Lumateperone | Phase 3 | Major Depressive Disorder | - | - |
Lumateperone low dose | Phase 3 | Irritability Associated With Autism Spectrum Disorder | - | - |
Lumateperone 42 mg | Phase 3 | Schizophrenia | - | - |
Lumateperone (ITI-007) | Phase 3 | Bipolar Depression | - | - |
Lumateperone high dose | Phase 3 | Irritability Associated With Autism Spectrum Disorder | - | - |
ITI-007 (Lumateperone) | Phase 3 | Bipolar Depression | - | - |
ITI-1284 20 mg | Phase 2 | Generalized Anxiety Disorder | - | - |
ITI-1284 | Phase 2 | Agitation Associated With Alzheimer's Dementia | - | - |
Lenrispodun | Phase 2 | Parkinson Disease | - | - |
ITI-1284 10 mg | Phase 2 | Generalized Anxiety Disorder | - | - |
ITI-214 | Phase 2 | Heart Failure, Systolic | - | - |
Bipolar Depression
3 drugs in this indication
Schizophrenia
3 drugs in this indication
Generalized Anxiety Disorder
2 drugs in this indication
Irritability Associated With Autism Spectrum Disorder
2 drugs in this indication
Major Depressive Disorder
1 drug in this indication
Heart Failure, Systolic
1 drug in this indication
Agitation Associated With Alzheimer's Dementia
1 drug in this indication
Parkinson Disease
1 drug in this indication
Psychosis Associated With Alzheimer's Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)